Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes
Objective: Biomarkers are needed to characterize heterogeneity within populations at risk for type 1 diabetes. The ratio of proinsulin to C-peptide (PI:C ratio), has been proposed as a biomarker of beta cell dysfunction and is associated with progression to type 1 diabetes. However, relationships be...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Journal of Translational Autoimmunity |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589909021000095 |
id |
doaj-6582df9c9c8745d7a4b1b4ec1ad9e9bf |
---|---|
record_format |
Article |
spelling |
doaj-6582df9c9c8745d7a4b1b4ec1ad9e9bf2021-03-11T04:25:54ZengElsevierJournal of Translational Autoimmunity2589-90902021-01-014100089Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetesTaylor M. Triolo0Laura Pyle1Sona Seligova2Liping Yu3Kimber Simmons4Peter Gottlieb5Carmella Evans-Molina6Andrea K. Steck7University of Colorado Denver School of Medicine – the Barbara Davis Center for Diabetes, Aurora, CO, USA; Corresponding author.University of Colorado Denver School of Medicine – the Barbara Davis Center for Diabetes, Aurora, CO, USA; University of Colorado Anschutz Medical Campus, Pediatrics, Aurora, CO, USAUniversity of Colorado Denver School of Medicine – the Barbara Davis Center for Diabetes, Aurora, CO, USAUniversity of Colorado Denver School of Medicine – the Barbara Davis Center for Diabetes, Aurora, CO, USAUniversity of Colorado Denver School of Medicine – the Barbara Davis Center for Diabetes, Aurora, CO, USAUniversity of Colorado Denver School of Medicine – the Barbara Davis Center for Diabetes, Aurora, CO, USAIndiana University School of Medicine, Indianapolis, IN, USA; Indiana University Center for Diabetes and Metabolic Diseases. Indianapolis, IN, USAUniversity of Colorado Denver School of Medicine – the Barbara Davis Center for Diabetes, Aurora, CO, USAObjective: Biomarkers are needed to characterize heterogeneity within populations at risk for type 1 diabetes. The ratio of proinsulin to C-peptide (PI:C ratio), has been proposed as a biomarker of beta cell dysfunction and is associated with progression to type 1 diabetes. However, relationships between PI:C ratios and autoantibody type and number have not been examined. We sought to characterize PI:C ratios in multiple islet autoantibody positive, single autoantibody positive and autoantibody negative relatives of individuals with type 1 diabetes. Methods: We measured PI:C ratios and autoantibodies with both electrochemiluminescence (ECL) assays (ECL-IAA, ECL-GADA and ECL-IA2A) and radiobinding (RBA) assays (mIAA, GADA, IA2A and ZnT8A) in 98 relatives of individuals with type 1 diabetes followed in the TrialNet Pathway to Prevention Study at the Barbara Davis Center for a mean of 7.4 ± 4.1 years. Of these subjects, eight progressed to T1D, 31 were multiple autoantibody (Ab) positive, 37 were single Ab positive and 22 were Ab negative (by RBA). Results: In cross-sectional analyses, there were no significant differences in PI:C ratios between type 1 diabetes and/or multiple Ab positive subjects (4.16 ± 4.06) compared to single Ab positive subjects (4.08 ± 4.34) and negative Ab subjects (3.72 ± 3.78) (p = 0.92) overall or after adjusting for age, sex and BMI. Higher PI:C ratios were associated with mIAA titers (p = 0.03) and showed an association with ECL-IA2A titers (p = 0.09), but not with ECL-IAA, GADA, ECL-GADA, IA2A nor ZnT8A titers. In mixed-effects longitudinal models, the trajectories of PI:C ratio over time were significantly different between the Ab negative and multiple Ab positive/type 1 diabetes groups, after adjusting for sex, age, and BMI (p = 0.04). Conclusions: PI:C ratio trajectories increase over time in subjects who have multiple Ab or develop type 1 diabetes and may be a helpful biomarker to further characterize and stratify risk of progression to type 1 diabetes over time.http://www.sciencedirect.com/science/article/pii/S2589909021000095 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Taylor M. Triolo Laura Pyle Sona Seligova Liping Yu Kimber Simmons Peter Gottlieb Carmella Evans-Molina Andrea K. Steck |
spellingShingle |
Taylor M. Triolo Laura Pyle Sona Seligova Liping Yu Kimber Simmons Peter Gottlieb Carmella Evans-Molina Andrea K. Steck Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes Journal of Translational Autoimmunity |
author_facet |
Taylor M. Triolo Laura Pyle Sona Seligova Liping Yu Kimber Simmons Peter Gottlieb Carmella Evans-Molina Andrea K. Steck |
author_sort |
Taylor M. Triolo |
title |
Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes |
title_short |
Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes |
title_full |
Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes |
title_fullStr |
Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes |
title_full_unstemmed |
Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes |
title_sort |
proinsulin:c-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes |
publisher |
Elsevier |
series |
Journal of Translational Autoimmunity |
issn |
2589-9090 |
publishDate |
2021-01-01 |
description |
Objective: Biomarkers are needed to characterize heterogeneity within populations at risk for type 1 diabetes. The ratio of proinsulin to C-peptide (PI:C ratio), has been proposed as a biomarker of beta cell dysfunction and is associated with progression to type 1 diabetes. However, relationships between PI:C ratios and autoantibody type and number have not been examined. We sought to characterize PI:C ratios in multiple islet autoantibody positive, single autoantibody positive and autoantibody negative relatives of individuals with type 1 diabetes. Methods: We measured PI:C ratios and autoantibodies with both electrochemiluminescence (ECL) assays (ECL-IAA, ECL-GADA and ECL-IA2A) and radiobinding (RBA) assays (mIAA, GADA, IA2A and ZnT8A) in 98 relatives of individuals with type 1 diabetes followed in the TrialNet Pathway to Prevention Study at the Barbara Davis Center for a mean of 7.4 ± 4.1 years. Of these subjects, eight progressed to T1D, 31 were multiple autoantibody (Ab) positive, 37 were single Ab positive and 22 were Ab negative (by RBA). Results: In cross-sectional analyses, there were no significant differences in PI:C ratios between type 1 diabetes and/or multiple Ab positive subjects (4.16 ± 4.06) compared to single Ab positive subjects (4.08 ± 4.34) and negative Ab subjects (3.72 ± 3.78) (p = 0.92) overall or after adjusting for age, sex and BMI. Higher PI:C ratios were associated with mIAA titers (p = 0.03) and showed an association with ECL-IA2A titers (p = 0.09), but not with ECL-IAA, GADA, ECL-GADA, IA2A nor ZnT8A titers. In mixed-effects longitudinal models, the trajectories of PI:C ratio over time were significantly different between the Ab negative and multiple Ab positive/type 1 diabetes groups, after adjusting for sex, age, and BMI (p = 0.04). Conclusions: PI:C ratio trajectories increase over time in subjects who have multiple Ab or develop type 1 diabetes and may be a helpful biomarker to further characterize and stratify risk of progression to type 1 diabetes over time. |
url |
http://www.sciencedirect.com/science/article/pii/S2589909021000095 |
work_keys_str_mv |
AT taylormtriolo proinsulincpeptideratiotrajectoriesovertimeinrelativesatincreasedriskofprogressiontotype1diabetes AT laurapyle proinsulincpeptideratiotrajectoriesovertimeinrelativesatincreasedriskofprogressiontotype1diabetes AT sonaseligova proinsulincpeptideratiotrajectoriesovertimeinrelativesatincreasedriskofprogressiontotype1diabetes AT lipingyu proinsulincpeptideratiotrajectoriesovertimeinrelativesatincreasedriskofprogressiontotype1diabetes AT kimbersimmons proinsulincpeptideratiotrajectoriesovertimeinrelativesatincreasedriskofprogressiontotype1diabetes AT petergottlieb proinsulincpeptideratiotrajectoriesovertimeinrelativesatincreasedriskofprogressiontotype1diabetes AT carmellaevansmolina proinsulincpeptideratiotrajectoriesovertimeinrelativesatincreasedriskofprogressiontotype1diabetes AT andreaksteck proinsulincpeptideratiotrajectoriesovertimeinrelativesatincreasedriskofprogressiontotype1diabetes |
_version_ |
1724226019516219392 |